CheckMan Stock Market Overview

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nano-X To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nano-X between March 31, 2025 and April 17, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 17, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nano-X Imaging Ltd.

Nike, Inc. is upgraded to Hold as valuation now reflects ongoing turnaround challenges and an extended recovery timeframe. NKE sales are at multiyear lows with Q4 revenues down 1% YoY, and guidance points to further declines in Q1 FY2027. Gross margin stabilization is encouraging, and expansion is expected in Q1; EPS growth in Q4 was mostly powered by one-off tariff recovery.

AT&T expands fiber, enterprise connectivity and connected car offerings ahead of Q2 earnings, but fierce telecom competition could test growth prospects.

QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.

O is expanding through major partnerships and private capital, but execution risks and a richer valuation keep the stock a Hold.

Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing further LDL-C reduction, with peak sales potential estimated at $5 billion by 2034, strengthening MRK's cardiometabolic portfolio.

New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Badger Meter, Inc. ("Badger Meter" or the "Company") (NYSE: BMI) on behalf of investors that purchased or otherwise acquired Badger Meter securities between April 18, 2024 and April 16, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Badger Meter and have suffered losses, you may CLICK HERE to contact us.

Autoliv, Inc. (ALV) Q2 2026 Earnings Call Transcript

DOCS is ramping up AI across physician workflows and enterprise tools, but weak pharma ads and higher AI spending may test near-term growth.

Honeywell Aerospace taps commercial aviation, defense and space trends with recurring aftermarket and digital revenue opportunities supporting its long-term growth story.